128 related articles for article (PubMed ID: 8584278)
1. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity.
Nwanze E; Souverbie F; Jonsson G; Sundström E
Neurotoxicology; 1995; 16(3):469-77. PubMed ID: 8584278
[TBL] [Abstract][Full Text] [Related]
2. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
[TBL] [Abstract][Full Text] [Related]
3. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
4. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
5. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
6. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Giovanni A; Sonsalla PK; Heikkila RE
J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
[TBL] [Abstract][Full Text] [Related]
7. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
8. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
9. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice.
Jonsson G; Nwanze E; Luthman J; Sundström E
Acta Physiol Scand; 1986 Oct; 128(2):187-94. PubMed ID: 3535380
[TBL] [Abstract][Full Text] [Related]
10. Effects of the parkinsonism-inducing neurotoxin MPTP and its metabolite MPP+ on sympathetic adrenergic nerves in mouse iris and atrium.
Luthman J; Jonsson G
Med Biol; 1986; 64(2-3):95-102. PubMed ID: 3489145
[TBL] [Abstract][Full Text] [Related]
11. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
Riachi NJ; Harik SI; Kalaria RN; Sayre LM
J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
Kindt MV; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
[TBL] [Abstract][Full Text] [Related]
13. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes.
Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW
Glia; 1992; 5(1):48-55. PubMed ID: 1311704
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
15. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
Pifl C; Hornykiewicz O; Giros B; Caron MG
J Pharmacol Exp Ther; 1996 Jun; 277(3):1437-43. PubMed ID: 8667208
[TBL] [Abstract][Full Text] [Related]
16. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
[TBL] [Abstract][Full Text] [Related]
18. Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue.
Zhang MY; Kagan N; Sung ML; Zaleska MM; Monaghan M
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):51-6. PubMed ID: 18824419
[TBL] [Abstract][Full Text] [Related]
19. Effect of dopaminergic neurotoxin MPTP/MPP+ on coenzyme Q content.
Dhanasekaran M; Karuppagounder SS; Uthayathas S; Wold LE; Parameshwaran K; Jayachandra Babu R; Suppiramaniam V; Brown-Borg H
Life Sci; 2008 Jul; 83(3-4):92-5. PubMed ID: 18565546
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
